Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

2.11
+0.390022.67%
Pre-market: 2.130.0200+0.95%07:21 EDT
Volume:1.55M
Turnover:2.98M
Market Cap:14.05M
PE:-0.44
High:2.20
Open:1.73
Low:1.72
Close:1.72
52wk High:12.56
52wk Low:0.6201
Shares:6.66M
Float Shares:5.84M
Volume Ratio:6.30
T/O Rate:26.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7656
EPS(LYR):-8.3501
ROE:-660.08%
ROA:-95.77%
PB:3.03
PE(LYR):-0.25

Loading ...

Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

Dow Jones
·
May 22

Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics

THOMSON REUTERS
·
May 18

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

GlobeNewswire
·
May 18

FibroBiologics expands fibroblast-based platform to target Hantavirus

TIPRANKS
·
May 11

Fibrobiologics Shares Down 13%

THOMSON REUTERS
·
May 11

Fibrobiologics Shares NOW Down 15% Premarket at 99 Cents

THOMSON REUTERS
·
May 11

FibroBiologics expands fibroblast platform to target Hantavirus pulmonary syndrome

Reuters
·
May 11

Fibrobiologics Advancing Development of a Fibroblast Treatment for Hantavirus

THOMSON REUTERS
·
May 11

Fibrobiologics Inc - to Initiate Discussions With Regulators for Hps Clinical Evaluation

THOMSON REUTERS
·
May 11

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

GlobeNewswire
·
May 11

FibroBiologics boosts ATM equity offering capacity to USD 7.5 million

Reuters
·
May 06

Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing

THOMSON REUTERS
·
May 06

FibroBiologics CEO Issues Letter to Shareholders

GlobeNewswire
·
May 05

FibroBiologics Grants Stock Options to Key Executives

TIPRANKS
·
May 05

FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38

Reuters
·
May 05

FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy

Reuters
·
May 05

FibroBiologics Cut to Hold From Buy by Maxim Group

Dow Jones
·
May 04

FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial

Reuters
·
May 04

Fibrobiologics Inc - Phase 1/2 Trial to Evaluate Cywc628 Safety, Tolerability, and Efficacy in Dfu Patients

THOMSON REUTERS
·
May 04

Fibrobiologics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
May 04